Navigation Links
PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
Date:1/22/2013

Cary, NC (PRWEB) January 22, 2013

Dr. Bruce Rehlaender has been appointed a Principal, Formulation Development at PharmaDirections. He will be based in the Portland, Oregon area and will have proximity to a growing market in early stage drug development. The appointment is a reflection of the invaluable contributions he has made over the past 6 years to the virtual biotech companies served by PharmaDirections.

Dr. Rehlaender joined PharmaDirections in 2007 as the Director, Formulation Development. In that capacity, he led multi-disciplinary teams of product development scientists who developed novel drug products using specialized expertise in biopharmaceutics, pharmacokinetics and formulation development.

There have been many significant achievements in his tenure, but we only have room for a few. Dr. Rehlaender led the development of the tri-layer, sustained release tablet formulations for Orexigen’s Contrave; that NDA was filed in 2010. He led many In-Silico PK Modeling programs that resulted in establishing optimum release patterns for over 12 unique client programs. He is the inventor on 5 patents that were developed for PharmaDirections’ clients was responsible for the formulation development efforts in over 20 unique client programs.

Over his 25 year industrial career, Dr. Rehlaender has developed his expertise in biopharmaceutics and formulation development with special expertise in challenges such as poorly soluble drugs, unstable compounds, and sophisticated controlled release patterns. He has extensive experience in developing parenteral products; oral tablets, capsules, and liquids; nebulizer products; dry powder inhalers; and topicals. His experience covers product processing from bench top to commercial manufacturing where he has developed processes for emulsification, powder milling, steam sterilization; aseptic manufacture; lyophilization; and separation of proteins.

Dr. Rehlaender's analytical expertise is primarily in solids characterization, including differential scanning calorimetry, thermogravimetric analysis, dynamic vapor sorption, powder flow measurement, and particle sizing using laser diffraction, photon correlation spectroscopy; electrozone sensing, and light obscuration.

About PharmaDirections

PharmaDirections is a consulting and project management company with a unique approach to managing preclinical, CMC and regulatory affairs programs. We provide strategic planning then oversee and direct pharmaceutical contract research using our own scientific experts and project managers. We are a comprehensive resource for virtual pharmaceutical and biotech companies who need to stay lean by outsourcing their R&D activities.

http://www.PharmaDirections.com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10341546.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
2. NSG Announces New Quartz Micro Flow Channel
3. Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
4. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
5. ASAE Foundation Announces Winners of the Innovation Grant Program
6. LATISTA Announces Next-Generation iPad App 2.0 for Construction with Industry Leading Innovations
7. GlycoCheck Announces Partnership in the United States with Vascular Health Sciences
8. Wysebridge Patent Bar Review Announces the Launch of News Blog
9. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
10. BroadData Conferencing Announces Enhanced International Audio Conference Call Capabilities
11. MakeSigns.com Announces New Tri-Fold Scientific Poster Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") ... New Zealand based Phase 1 trial ... remarkable results in reducing inflamed protein biomarkers in patients ... is believed that this is the first time in ... can be made between epigenetic regulation and its potential ...
(Date:1/23/2017)... ... January 23, 2017 , ... Calvert Labs, Inc. announced ... and Senior Director, Safety Pharmacology. Dr. Thomas earned his M.Sc. and Ph.D. ... career as an academic and industry preclinical drug developer spans more than three ...
(Date:1/23/2017)... ... January 23, 2017 , ... AxioMed will be presenting its ... meeting in Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting ... to experience the simplicity of the surgical technique,” said Jake Lubinski, President of ...
(Date:1/21/2017)... , ... January 20, 2017 , ... ... and resource to the healthcare industry ( http://www.gandlscientific.com ), has announced the opening ... team of clinical and scientific consultants and contractors. This is the latest step ...
Breaking Biology Technology:
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... biometric sensor technology, today announced the launch of ... sensor systems, the highly-accurate biometric sensor modules that ... biometric technology, experience and expertise. The two new ... designed specifically for hearables, and Benchmark BW2.0, a ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/15/2016)... BADEN-BADEN, Germany , December 15, 2016 /PRNewswire/ ... services provider, today announced an agreement with NuData Security, ... join forces. The partnership will enable clients to focus on ... with local data protection regulation. ... In order to provide a one-stop ...
Breaking Biology News(10 mins):